Tucidinostat

Generic Name: Tucidinostat

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₁₉FN_₄O_₂

CAS Number: 1616493-44-7

Unique Ingredient Identifier: 87CIC980Y0

Indication: Investigated for use/treatment in cancer/tumors (unspecified).

Clinical Trials

Chidamide and Duvalisibon for the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma

Phase 2

Recruiting

Conditions: Peripheral T Cell Lymphoma
Refractory T-Cell Lymphoma
Relapsed Peripheral T-Cell Lymphoma

Interventions: Drug: Chidamide combined with Duvillisib

First Posted Date: 2023-11-30

Last Posted Date: 2025-02-19

Lead Sponsor: The First Affiliated Hospital of Xiamen University

Target Recruit Count: 33

Registration Number: NCT06151106

Locations: 🇨🇳
The First Affiliated Hosptial of Xiamen University, Xiamen, Fujian, China

SHR2554 Clinical Study of Chidamide in the Treatment of T-cell Lymphoma

Phase 3

Recruiting

Conditions: Relapsed/Refractory PTCLT With at Least One Line of Prior Systemic Therapy

Interventions: Drug: SHR2554; Chidamide analog tablets
Drug: SHR2554 analog tablets; Chidamide

First Posted Date: 2023-11-08

Last Posted Date: 2024-03-19

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Target Recruit Count: 130

Registration Number: NCT06122389

Locations: 🇨🇳
Peking University Cancer Hospital, Beijing, Beijing, China

A Prospective Clinical Study of Bridging alloHSCT After Treatment With Obinutuzumab in Combination With Chidamide and Venetoclax in RR Ph-ALL and B-cell Lymphoma Patients

Phase 1

Not yet recruiting

Conditions: Acute Lymphoblastic Leukemia

Interventions: Drug: chidamide
Drug: Venetoclax Oral Tablet
Drug: Inotuzumab Ozogamicin

First Posted Date: 2023-10-17

Last Posted Date: 2023-11-02

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 42

Registration Number: NCT06087419

A Study of Chidamide With AZA in MRD Positive AML After Transplant

Not Applicable

Recruiting

Conditions: Minimal Residual Disease
AML, Adult

Interventions: Drug: chidamide and azacitidine

First Posted Date: 2023-10-04

Last Posted Date: 2023-10-27

Lead Sponsor: Guangdong Provincial People's Hospital

Target Recruit Count: 60

Registration Number: NCT06066905

Locations: 🇨🇳
Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China

Low-dose Chidamide Maintenance Therapy After Allo-HSCT for T-cell Acute Lymphoblastic Leukemia or T-cell Lymphomas

Phase 2

Recruiting

Conditions: T Lymphoblastic Leukemia/Lymphoma

Interventions: Drug: Chidamide

First Posted Date: 2023-08-15

Last Posted Date: 2023-08-15

Lead Sponsor: Zhejiang University

Target Recruit Count: 44

Registration Number: NCT05991973

Locations: 🇨🇳
The First Hospital of Zhejiang Medical Colleage Zhejiang University, Hangzhou, Zhejiang, China

Chidamide/Everolimus for PIK3CA Wild-type/Mutant HR+/HER2- Advanced Breast Cancer

Phase 2

Recruiting

Conditions: HR+/HER2- Advanced Breast Cancer
Targeted Therapy

Interventions: Drug: Everolimus
Drug: Chidamide
Drug: Endocrine therapy
Drug: Ovarian function suppression(OFS)

First Posted Date: 2023-08-09

Last Posted Date: 2023-08-09

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 102

Registration Number: NCT05983107

Locations: 🇨🇳
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China

Prospective, Single Arm, Single Center Study of Duvelisib Combined With Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma (PTCL)

Phase 2

Recruiting

Conditions: Newly Diagnosed Peripheral T-cell Lymphoma

Interventions: Drug: Duvelisib, Chidamide

First Posted Date: 2023-08-04

Last Posted Date: 2023-08-04

Lead Sponsor: Liling Zhang

Target Recruit Count: 36

Registration Number: NCT05976997

Locations: 🇨🇳
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China

A Retrospective Clinical Study on the First-line Maintenance Treatment of PTCL With Chidamide.

Recruiting

Conditions: PTCL

First Posted Date: 2023-08-01

Last Posted Date: 2023-08-01

Lead Sponsor: The First Affiliated Hospital with Nanjing Medical University

Target Recruit Count: 200

Registration Number: NCT05967949

Locations: 🇨🇳
Hematological Department, People's Hospital of Jiangsu Province, Nanjing, Jiangsu, China

Chidamide in Combination With Azacitidine, Liposomal Mitoxantrone, and Prednisone (CAMP Regimen) for the Treatment of Previously Untreated Nodal TFH Cell Lymphoma

Phase 2

Recruiting

Conditions: Peripheral T Cell Lymphoma
Epigenetic Repression

Interventions: Drug: Chidamide
Drug: Azacitidine
Drug: liposomal mitoxantrone
Drug: prednisone

First Posted Date: 2023-07-25

Last Posted Date: 2024-12-30

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 37

Registration Number: NCT05958719

Locations: 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin, China

Study of Selinexor Combined With Chidamide in Relapsed/Refractory Acute Leukemia (AML) Patients

Phase 2

Recruiting

Conditions: Acute Myeloid Leukemia (Relapsed/Refractory)

Interventions: Drug: Selinexor
Drug: Chidamide

First Posted Date: 2023-07-19

Last Posted Date: 2023-07-19

Lead Sponsor: The First Affiliated Hospital of Soochow University

Target Recruit Count: 42

Registration Number: NCT05951855

Locations: 🇨🇳
The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy